Clinical-stage biotech companies

Companies whose enriched business profile is tagged “Clinical-stage biotech”, drawn from their SEC filings + website text. Sorted by market capitalization; every figure is delayed data from SEC EDGAR + market data, shown with its as-of date.

• ENLIVEN THERAPEUTICS INC (ELVN) Health Care — Enliven Therapeutics is a precision oncology company developing next-generation small molecule inhibitors, led by its clinical-stage BCR-ABL program for chronic myeloid leukemia. ask →
• ARCUS BIOSCIENCES INC (RCUS) Health Care — A clinical-stage biopharmaceutical company focused on discovering and developing innovative, small-molecule and antibody-based oncology therapies through a robust pipeline and strategic collaborations. ask →
• SELLAS LIFE SCIENCES GROUP INC (SLS) Health Care — SELLAS Life Sciences is a clinical-stage biotech developing novel immunotherapies to address hematologic and solid tumor cancers. ask →
• TYRA BIOSCIENCES INC (TYRA) Health Care — Tyra Biosciences is a clinical-stage biotech company developing precision small-molecule inhibitors to overcome drug resistance in cancer, particularly targeting FGFR-driven diseases. ask →
• Odyssey Therapeutics, Inc. (ODTX) Health Care — A clinical-stage biotechnology company developing a pipeline of novel small molecule and protein therapeutic candidates. ask →
• CLIMB BIO INC (CLYM) Health Care — Clinical-stage biotech developing budoprutug, an anti-CD19 monoclonal antibody for B-cell depletion in autoimmune diseases including membranous nephropathy and lupus. ask →
• ANNEXON INC (ANNX) Health Care — Annexon is a clinical-stage biotechnology company developing C1q-inhibitor therapies to treat neurodegenerative and autoimmune diseases driven by the classical complement pathway. ask →
• BridgeBio Oncology Therapeutics, Inc. (BBOT) Health Care — BridgeBio Oncology is advancing next-generation small-molecule inhibitors of RAS and PI3K pathways for previously untreatable solid tumors including KRAS-driven lung and pancreatic cancers. ask →
• MONOPAR THERAPEUTICS INC (MNPR) Health Care — Monopar Therapeutics is a clinical-stage biopharmaceutical firm focused on developing innovative radiopharmaceuticals for cancer and specialized treatments for rare diseases like Wilson disease. ask →
• ZURA BIO LTD CLASS A (ZURA) Health Care — Zura Bio is developing differentiated bispecific and monoclonal antibodies targeting immune pathways in autoimmune and inflammatory diseases where current therapies leave patients with inadequate disease control. ask →
• REZOLUTE INC (RZLT) Health Care — Rezolute is a clinical-stage biopharmaceutical company developing targeted therapeutic solutions for rare and chronic metabolic and endocrine diseases. ask →
• UPSTREAM BIO INC (UPB) Health Care — Upstream Bio is a clinical-stage biotech developing verekitug, a potentially best-in-class monoclonal antibody targeting the TSLP receptor for the treatment of severe respiratory inflammatory diseases. ask →
• ELEDON PHARMACEUTICALS INC (ELDN) Health Care — Eledon Pharmaceuticals is a clinical-stage biotech developing immune-modulating therapies for autoimmune diseases and organ transplantation. ask →
• Aldeyra Therapeutics, Inc. (ALDX) Health Care — Aldeyra is a clinical-stage biotech pursuing FDA approval of reproxalap, an aldehyde dehydrogenase activator for ophthalmologic inflammation, dependent on addressing regulatory feedback and securing capital for development and commercialization. ask →

Not quite it? Describe exactly what you want →

Data: SEC EDGAR (filings) + market data (fundamentals, delayed daily-close). Figures shown with their as-of date.

Last updated 2026-08-24.

Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.